US42328V8019 - Common Stock
HELIUS MEDICAL TECHNOLOGIES
NASDAQ:HSDT (10/31/2024, 6:30:54 PM)
After market: 0.5054 0 (-0.32%)0.507
-0.04 (-7.78%)
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The company is headquartered in Newtown, Pennsylvania. The company went IPO on 2014-06-27. The company is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. The company develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
HELIUS MEDICAL TECHNOLOGIES
642 Newtown Yardley Road
Newtown PENNSYLVANIA 18940
P: 12159446100
CEO: Dane C. Andreeff
Employees: 22
Website: https://heliusmedical.com/
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference...
-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National...
-- Achieves primary endpoint showing a linear relationship between adherence to PoNS Therapy® in Phase 2 and improvement in DGI scores from Phase 1 to end...
Here you can normally see the latest stock twits on HSDT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: